Navegando por Palavras-chave "intravitreal bevacizumab"

Agora exibindo 1 - 3 de 3
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection
    (Nature Publishing Group, 2007-03-01) Aggio, Fabio Bom [UNIFESP]; Farah, M. E.; Melo, G. B. de; d'Azevedo, P. A.; Pignatri, A. C. C.; Hofling-Lima, A. L.; Universidade Federal de São Paulo (UNIFESP)
    Purpose: To report two cases of acute endophthalmitis following intravitreal bevacizumab injection.Methods: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. Vitreous samples were obtained, followed by the injection of vancomycin 1 mg/0.1 ml and ceftazidime 2.25 mg/0.1 ml. Pulsed-field gel electrophoresis (PFGE) was used to determine whether the isolated microorganisms were the same.Results: Coagulase-negative staphylococci were identified and isolated from the vitreous specimen of both patients. PFGE revealed different patterns of banding, excluding that interpatient contamination occured.Conclusions: Infectious endophthalmitis is a potential complication of intravitreal bevacizumab injection.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments
    (Springer, 2007-02-01) Aggio, Fabio Bom [UNIFESP]; Farah, Michel Eid; Silva, Wagner Camilo; Melo, Gustavo Barreto; Universidade Federal de São Paulo (UNIFESP)
    Photodynamic therapy with verteporfin (PDT) significantly reduces the risk of vision loss in patients with exudative age-related macular degeneration (AMD). Indocyanine green-mediated photothrombosis (IMP) and transpupillary thermotherapy (TTT) may also be beneficial for selective cases of exudative AMD. However, a substantial subset of patients responds poorly to these treatments. Intravitreal bevacizumab (IVB) has been recently used in the treatment of exudative AMD, showing both visual and anatomic improvement in the majority of cases.This interventional retrospective case series reports the effects of IVB in 17 eyes with subfoveal neovascular AMD that had undergone repeated PDT (combined or not with triamcinolone acetonide) or PDT followed by either IMP or TTT with poor results. the main outcome measures were visual acuity and tomographic signs of intra/subretinal fluid, as well as central retinal thickness.Most patients received a single IVB injection. the mean follow-up was 4.47 months. the mean logMAR visual acuity changed from 1.17 +/- 0.40 to 1.06 +/- 0.44 (P=0.17). the mean central retinal thickness decreased from 404.05 +/- 245.26 to 280.23 +/- 143.14 mu m (P=0.032). At the end of the study, lack of tomographic signs of intra/subretinal fluid was noted in four (23.5%) eyes. No ocular or systemic side effects were identified.Short-term results with IVB for the treatment of exudative AMD have been promising. However, the chronic retinal and pigment epithelium changes frequently present in eyes that underwent multiple previous treatments may limit complete visual recovery. To our knowledge, this is the first report on the use of IVB for this particular group of AMD patients.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Twelve-month safety of intravitreal injections of bevacizumab (Avastin (R)): results of the Pan-American Collaborative Retina Study Group (PACORES)
    (Springer, 2008-01-01) Wu, Lihteh; Martinez-Castellanos, Maria A.; Quiroz-Mercado, Hugo; Arevalo, J. Fernando; Berrocal, Maria H.; Farah, Michel E.; Maia, Mauricio; Roca, Jose A.; Rodriguez, Francisco J.; Pan Amer Collaborative Retina Grp; Inst Cirugia Ocular; Asociac Para Evitar Ceguera; Clin Oftalmol Caracas Ctr; Univ Puerto Rico; Universidade Federal de São Paulo (UNIFESP); Clin Ricardo Palma; Fdn Oftalmol Nacl
    Background Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the posterior pole that are characterized by macular edema and/or intraocular neovascularization. Recently anti-VEGF agents such as ranibizumab and pegaptanib sodium have been shown to be beneficial in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). However in most parts of the world, both pegaptanib sodium and ranibizumab are not readily available. Bevacizumab, a humanized recombinant monoclonal IgG antibody that binds and inhibits all VEGF isoforms, has been proposed as an alternative treatment option.Methods A total of 1,265 consecutive patients were injected with bevacizumab for diseases such as proliferative diabetic retinopathy, diabetic macular edema, retinal vein occlusions, and CNV of several etiologies including ARMD at eight Latin American institutions from 1 September 2005 to 31 January 2006. of these 1,265, 92 were excluded because they were injected once and lost to follow-up. the remaining 1,173 patients constitute the subjects of this retrospective, multicenter, open label, uncontrolled interventional case series that reports the cumulative systemic and ocular adverse events following intravitreal bevacizumab during 12 months of follow-up. Patients were examined at baseline and then monthly. If the patients were unable to attend the 12-month visit, a telephone interview was conducted to assess for possible systemic complications.Results A total of 4,303 intravitreal injections of bevacizumab on 1,310 eyes was reported. All 1,173 patients were accounted for at the 12-month visit. Systemic adverse events were reported in 18 (1.5%) patients. These included seven (0.59%) cases of an acute elevation of systemic blood pressure, six (0.5%) cerebrovascular accidents, five (0.4%) myocardial infarctions, two (0.17%) iliac artery aneurysms, two (0.17%) toe amputations and five (0.4%) deaths. Ocular complications included seven (0.16%) bacterial endophthalmitis, seven (0.16%) tractional retinal detachments, four (0.09%) uveitis, and a case (0.02%) each of rhegmatogenous retinal detachment and vitreous hemorrhage.Conclusions Despite the limited follow-up, repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year.